Treatment Paradigms in Neovascular AMD

Promising Treatment Strategies for Neovascular AMD: Anti-VEGF Therapy

IL-18 Immunotherapy for Neovascular AMD.

I have read with great interest the data presented by Doyle et al. on the new adjuvant immunotherapy-based treatment involving clinical deployment of IL-18 for neovascular agerelated macular degeneration (AMD). The data in their study are displayed elegantly with convincing results, in spite of the contrasting opinions presented in another study. I applaud their interesting and important work, ...

Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach.

Purpose The purpose of this study was to predict low and high anti-VEGF injection requirements during a pro re nata (PRN) treatment, based on sets of optical coherence tomography (OCT) images acquired during the initiation phase in neovascular AMD. Methods Two-year clinical trial data of subjects receiving PRN ranibizumab according to protocol specified criteria in the HARBOR study after thre...

Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results

Purpose To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2)...

Switch to aflibercept or ranibizumab after initial treatment with bevacizumab in eyes with neovascular AMD

BACKGROUND To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. METHODS Observational clinical study was performed. We measured the structural outcome (CMT on SD-OCT; μm) and the visual outcome (best correct...